Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Veeva Systems (NYSE: VEEV) have signed into a ten-year strategic partnership agreement that extends their twelve-year partnership.

In accordance with the terms of the agreement, Merck will prioritise Veeva products when developing new industry-specific software and data, putting Veeva first whenever possible. aimed at maximising the utility of Veeva’s integrated solutions and cloud-based platform. Merck will take part in the creation of Veeva’s product roadmap and receive a strategic pricing strategy from Veeva. Through this partnership, Veeva’s products and services will be more effectively assessed, purchased, used, and valued by Merck, accelerating the company’s digital agenda.

According to Robert M. Davis, CEO and President of Merck, “Transforming our digital potential, our data, and our analytical capabilities is critical to enable our international colleagues to accomplish our purpose: to employ the power of cutting-edge research to save and improve lives around the world.” Our strategic collaboration with Veeva strengthens our ability to use cutting-edge technology and improves our capacity to add value for patients and all of our stakeholders; this is a crucial component of how we gauge success.

Source: Prnewswire